Lupin launches Droxidopa capsules in US
Droxidopa Capsules, 100 mg, 200 mg and 300 mg is a generic equivalent of Northera capsules, 100 mg, 200 mg and 300 mg, of Lundbeck NA, indicated for the treatment of orthostatic dizziness
Lupin yesterday launched Droxidopa capsules, 100 mg, 200 mg and 300 mg, having received an approval from the United States Food and Drug Administration (FDA). The product is manufactured at Lupin’s facility in Nagpur, India, according to a statement released by the company.
Droxidopa Capsules, 100 mg, 200 mg and 300 mg is a generic equivalent of Northera capsules, 100 mg, 200 mg and 300 mg, of Lundbeck NA, indicated for the treatment of orthostatic dizziness, light headedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson’s disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.
Droxidopa Capsules had estimated annual sales of $294 million in the US, according to IQVIA, added the statement.
- Advertisement -